Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemoradiotherapy plus surgery for thoracic esophageal squamous cell carcinoma
ChiCTR-OIh-17011544Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Started Jun 2017; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-OIh-17011544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIh-17011544.